This was investigated further in the individual subgroups; low MSK1 expression was associated with adverse breast cancer-specific survival in HER2-negative patients and patients with non-basal like disease (P = 0.006 and P = 0.024, respectively, Fig. 3b, f). Here, ERBB2 is linked to breast cancer.